Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
SKRR to Commence Uranium Drill Program to Test Conductors at Clearwater West (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Alaunos Therapeutics Inc TCRT

Healthcare Biotechnology
Alaunos Therapeutics, Inc. is a clinical-stage oncology-focused cell therapy company. The Company is focused on exploring strategic alternatives, including, but not limited to, an acquisition, merger, reverse merger, sale of assets, strategic partnerships, capital raises or other transactions. Separately, the Company is evaluating several potential in-licensing opportunities in obesity... see more

Recent & Breaking News (NDAQ:TCRT)

Alaunos Therapeutics Announces Third Quarter 2023 Financial Results, Phase 1 Clinical Data and Continued Exploration of Strategic Alternatives

GlobeNewswire November 14, 2023

Alaunos Therapeutics Announces Second Quarter 2023 Financial Results, Interim Clinical Data and Exploration of Strategic Alternatives

GlobeNewswire August 14, 2023

Alaunos Therapeutics Announces Presentation at the 2nd Hawaii Global Summit on Thoracic Malignancies

GlobeNewswire June 29, 2023

Alaunos Therapeutics to Present Early Data from TCR-T Library Phase 1/2 Trial at 2023 American Society of Clinical Oncology Annual Meeting

GlobeNewswire May 25, 2023

Alaunos Therapeutics Reports First Quarter 2023 Financial Results

GlobeNewswire May 10, 2023

Alaunos Therapeutics to Report First Quarter 2023 Financial Results on May 10, 2023

GlobeNewswire May 3, 2023

Alaunos Therapeutics Announces Poster Presentation at the American Society of Clinical Oncology (ASCO) 2023 Annual Meeting

GlobeNewswire April 26, 2023

Alaunos Therapeutics Appoints Dr. Robert J. Hofmeister to Board of Directors

GlobeNewswire March 30, 2023

Alaunos Therapeutics to Participate in Upcoming Investor Conferences in April

GlobeNewswire March 29, 2023

Alaunos Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results

GlobeNewswire March 7, 2023

Alaunos Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results on March 7, 2023

GlobeNewswire February 28, 2023

Alaunos Therapeutics Highlights Strategic Priorities and Anticipated Portfolio Milestones for 2023

GlobeNewswire January 9, 2023

Alaunos Therapeutics Announces Pricing of Public Offering of Common Stock

GlobeNewswire November 29, 2022

Alaunos Therapeutics Announces Proposed Public Offering of Common Stock

GlobeNewswire November 28, 2022

Alaunos Therapeutics Reports Third Quarter 2022 Financial Results

GlobeNewswire November 14, 2022

Alaunos Therapeutics to Report Third Quarter 2022 Financial Results on November 14, 2022

GlobeNewswire November 8, 2022

Alaunos Therapeutics to Present Data Highlighting its hunTR(TM) TCR Discovery Platform at the Society for Immunotherapy of Cancer 2022 Annual Meeting

GlobeNewswire November 7, 2022

Alaunos Therapeutics Highlights Data from TCR-T Library Phase 1/2 Trial at the CRI-ENCI-AACR Sixth International Cancer Immunotherapy Conference

GlobeNewswire September 21, 2022

Alaunos Therapeutics to Participate in Upcoming Investor Conferences in September

GlobeNewswire September 7, 2022

Alaunos Therapeutics Announces Early Clinical Data Showing Objective Clinical Response Using its TCR-T Cell Therapy

GlobeNewswire September 6, 2022